Covid mRNA tech may create first-ever cure for heart attacks: UK scientists

UK scientists may have discovered the world's first cure for heart attacks using the same mRNA technology as Covid vaccines.

Image via Shutterstock
Can the mRNA technology cure heart attack?
IANS London
2 min read Last Updated : Apr 16 2022 | 10:49 AM IST

UK scientists may have discovered the world's first cure for heart attacks using the same mRNA technology as Covid vaccines.

Human heart has no capacity to heal itself after a heart attack.

But with the new technique called genetic tracking - built on the same technology used to create Pfizer and Moderna's Covid vaccines - can help new heart cells replace the dead ones and instead of forming a scar, develop a new muscle tissue.

A team at King's College London tracked genetic codes called mRNAs which are injected into the heart to produce proteins that would generate healthy heart cells, Daily Mail reported.

"We are all born with a set number of muscle cells in our heart and they are exactly the same ones we will die with. Our goal has been to find a treatment that can convince surviving cells to proliferate," lead researcher Professor Mauro Giacca was quoted as saying.

"Regenerating a damaged human heart has been a dream until a few years ago, but can now become a reality.

"We are using exactly the same technology as the Pfizer and Moderna vaccines to inject micro RNAs to the heart, reaching surviving heart cells and pushing their proliferation," Giacca said.

Besides helping hearts regenerate, the mRNAs also work towards a treatment to stop cells dying during a heart attack.

Heart attack and stroke accounted for 85 per cent of 17.9 million deaths from cardiovascular diseases globally.

Scientists believe the new RNA (ribonucleic acid) therapy could revolutionise cardiovascular medicine and stop millions of heart attacks progressing towards heart failure, the report said.

The technology tested first to regenerate damaged pig hearts have so far been successful. Tests on humans are due in the next two years.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusHeart attackUK

First Published: Apr 16 2022 | 10:48 AM IST

Next Story